.
BACKGROUND AND AIMS:The TRISCEND II trial demonstrated superior clinical benefits for patients with ≥severe tricuspid regurgitation (TR) treated with the EVOQUE transcatheter tricuspid valve replacement (TTVR) system plus medical therapy vs medical therapy alone. This work reports 1-year and 18-month outcomes in patients stratified by baseline TR severity. METHODS:The multicentre, prospective TRISCEND II trial enrolled 400 patients with symptomatic, ≥severe TR, and randomized 2:1 to TTVR (n = 267) or control (n = 133). In a post hoc analysis, patients were stratified into severe TR (n = 172) and massive/torrential TR (n = 220) cohorts. Clinical and quality-of-life outcomes were reported at 1 year, with Kaplan-Meier estimates for all-cause mortality and heart failure (HF) hospitalization assessed at 18 months. Study oversight included an independent echocardiographic core laboratory, clinical events committee, and data safety monitoring board. RESULTS:One year after TTVR, TR was ≤mild in 95.2% of severe TR and 95.3% of massive/torrential TR patients. The primary safety and effectiveness endpoint (win ratio) favoured TTVR over control regardless of baseline TR severity: severe {1.64 [95% confidence interval (CI): 1.11, 2.43]} and massive/torrential [2.20 (1.55, 3.14)]. At 18 months, TTVR patients had similar mortality to controls [rate difference: severe 0.2% (-11.6, 11.9), massive/torrential -5.8% (-17.6, 6.0)], whereas HF hospitalization rates favoured TTVR in the massive/torrential cohort [vs control, severe 9.8% (-3.0, 22.7), massive/torrential -15.2% (-28.9, -1.5)]. CONCLUSIONS:Patients with ≥severe TR benefit from TTVR, experiencing improvements in TR severity, functional capacity, and quality of life regardless of baseline TR severity, with a signal for greater benefit in patients with more advanced disease.
OBJECTIVE:Short stature in children born small for gestational age (SGA) is treated with daily injections of recombinant growth hormone (GH), a significant treatment burden. The objective of this study is to demonstrate the efficacy and safety of once-weekly somapacitan, a long-acting GH, in short children born SGA. DESIGN:REAL8 (NCT05330325) is a multinational, multicenter, randomized, open-labeled, active comparator, phase 3 basket study including four non-GH deficiency indications comprising a 52-week main phase and 104-week extension. Here, we present 52-week results from the SGA sub-study. METHODS:142 prepubertal, treatment-naïve children born SGA in 78 sites across 26 countries were randomized 2:1:1 to somapacitan .24 mg/kg/week or daily GH 0.035 or 0.067 mg/kg/day, all administered subcutaneously. 140 completed the main 52-week treatment period. RESULTS:The primary endpoint, estimated mean height velocity at week 52, was 11.0 cm/year for somapacitan vs. 9.4 cm/year [ETD = 1.6(0.91, 2.23)95%CI] and 11.1 cm/year [ETD = -0.1(-0.75, 0.60)95%CI] for daily GH 0.035 and 0.067 mg/kg/day, respectively. Noninferiority was confirmed for somapacitan compared to both daily GH groups. Superiority was demonstrated for somapacitan versus daily GH 0.035 mg/kg/day. Safety profiles were similar between treatment groups. As expected, somapacitan reduced disease burden at week 52, as for daily GH 0.067 mg/kg/day, while somapacitan was associated with reduced treatment burden. CONCLUSION:Somapacitan provides similar efficacy, safety, and tolerability as daily GH in short children born SGA after 52 weeks of treatment. Somapacitan may be an attractive alternative to daily GH in this population, reducing treatment burden to improve adherence and treatment outcomes.
2065 Background: Glioblastoma (GBM) contains extensive hypoxic regions due to tumor-associated thrombosis and abnormal vasculature. Hypoxia drives resistance to radiation (RT) and temozolomide (TMZ) by limiting oxygen-dependent DNA damage, enabling DNA repair, and reducing drug efficacy and delivery. The RESTORE trial (NCT03862430) is the first randomized, prospective, placebo-controlled study of NanO₂ (2% w/v dodecafluoropentane emulsion) in GBM, a fluorocarbon-based oxygen therapeutic hypothesized to reoxygenate hypoxic GBM tissue, with the goal of enhancing the efficacy of chemoradiation. Methods: Patients with newly diagnosed GBM (WHO 2021) received standard-of-care radiation (60 Gy) with concurrent TMZ (75 mg/m²/day). Patients were randomized 2:1 to receive either NanO 2 or 0.9% sodium chloride administered intravenously immediately prior to each RT fraction, with continuous supplemental oxygen given during the infusion and RT. Following chemoradiation, patients completed a four-week recovery period before initiating adjuvant TMZ for 6 cycles. The primary endpoint is progression free survival and secondary endpoints include overall survival, objective response rate, pseudoprogression rate, and patient reported outcomes. Results: Between May 2023 and October 2025, 93 patients were treated (safety set). The study has completed the planned enrollment. Median age was 63 years (range, 19–84) and 57% were men. As of the data cutoff on 12/29/25, all patients completed the follow up visit 4 weeks after chemoradiation. Sixty-eight patients (73%) remained on study undergoing adjuvant TMZ or in long-term follow-up. Twenty-one patients passed of tumor progression and 4 patients withdrew consent. The median duration on study was 8.7 months (range, 1.3–31.4). During chemoradiation and the four-week recovery, 63 treatment-emergent adverse events (TEAEs) of CTCAE severity grade ≥3 were reported in 37% of patients, with brain edema, lymphocyte count decreased, and platelet count decreased being the most frequently reported. Twenty-six treatment-emergent serious adverse events (TESAEs) occurred in 19% of patients, with embolism, pulmonary embolism, and seizure being the most frequently reported. Three TESAEs were assessed as possibly or probably related to study drug; none were unexpected. Survival follow up is ongoing. Conclusions: In this blinded, pooled safety analysis of a randomized phase 2 trial in newly diagnosed GBM, the study treatment was well tolerated and no new safety signals were identified. Treatment allocation remains blinded. Efficacy outcomes and arm-specific safety analyses will be reported after completion of the primary endpoint analysis. Clinical trial information: NCT03862430 .
Abstract Background Glioblastoma (GBM) contains extensive hypoxic regions due to hypercellularity, tumor-associated thrombosis and vasculopathy. Hypoxia drives treatment resistance by limiting oxygen-dependent DNA damage, enabling DNA repair and reducing drug delivery and efficacy. The RESTORE trial (NCT03862430) is a randomized, placebo-controlled study evaluating NanO2 (2% w/v dodecafluoropentane emulsion), a fluorocarbon-based nanoparticle, versus placebo, in patients with newly diagnosed GBM. Methods Patients with newly diagnosed GBM (WHO 2021) received standard-of-care radiotherapy (RT, 60 Gy) with concurrent TMZ (75 mg/m²/day). Patients were randomized 2 : 1 to receive intravenous NanO2 or 0.9% sodium chloride prior to each RT fraction, with continuous supplemental oxygen given during infusion, post-infusion and RT. After chemoradiation and a 4-week recovery period, patients received 6-12 months of adjuvant TMZ. The primary endpoint is progression free survival and secondary endpoints include overall survival, objective response rate, pseudoprogression rate, and patient reported outcomes. Results From May 2023 to October 2025, 93 patients were treated and enrollment has been completed. As of April 2026, all patients had completed chemoradiation treatment. Fifty-seven patients remain on adjuvant TMZ or in follow-up. Thirty-two patients died from tumor progression and 4 withdrew consent. A total of 118 treatment-emergent adverse events (TEAE) of grade ≥3 were reported in 57% of patients. The most frequent TEAEs were lymphocytopenia (17, 14.4%), thrombocytopenia (11, 9.3%) and brain edema (11, 9.3%). 49 treatment-emergent serious adverse events (TESAE) were reported, with seizure (6, 12.2%), pulmonary embolism (5, 10.2%) and fall (5, 10.2%) being the most common. Five events were assessed as possibly or probably related to study drug, and none were unexpected. Survival follow up is ongoing. Conclusion The study treatment was well tolerated, and no new safety signals were identified in this pooled analysis. Arm-specific safety analyses and efficacy will be reported after the primary endpoint analysis has been completed.